JENNEREX INC has a total of 31 patent applications. Its first patent ever was published in 2003. It filed its patents most often in Republic of Korea, China and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are KIRN DAVID, TISSUEGENE INC and BIO PATH HOLDINGS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 8 | |
#2 | China | 6 | |
#3 | Canada | 5 | |
#4 | Brazil | 4 | |
#5 | Japan | 3 | |
#6 | WIPO (World Intellectual Property Organization) | 3 | |
#7 | Hong Kong | 1 | |
#8 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Kirn David | 25 |
#2 | Breitbach Caroline | 8 |
#3 | Bell John | 7 |
#4 | David Kirn | 6 |
#5 | Thorne Steve H | 5 |
#6 | Moon Anne | 4 |
#7 | Lee Yu Kyoung | 4 |
#8 | Hwang Tae-Ho | 3 |
#9 | Kim Mi-Kyung | 3 |
#10 | John Bell | 2 |
Publication | Filing date | Title |
---|---|---|
CN103429258A | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus | |
CN101912421A | Methods and compositions concerning poxviruses and cancer |